anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Tourette syndrome (TS) is a common chronic neurodevelopmental disorder in children. Parents play critical roles in helping to manage their child's symptoms, leading to several issues associated with care needs and the parent-child interaction. This study adopted a randomized control study design. The investigators developed a TS symptom management APP based on symptom management theory and the relevant literature. The research subjects were parents of children with TS between 6 and 12 years old. The experimental group received TS symptom management APP intervention for four weeks. The experimental group recorded the patterns and treatments of tics at least twice a week and completed relevant readings on TS care information during these four weeks. The control group continued to receive outpatient verbal and paper health education guidance from healthcare providers. The participants in both groups were requested to complete the following questionnaires, including the care needs scale, WHOQOL-BREF, Pittsburgh Sleep Quality Index (Chinese version), Beck Anxiety Inventory (Chinese version), Parent-Child Relationship Quality Inventory, and the Yale Global Tic Severity Scale. These questionnaires were completed before the intervention and directly after the four-week intervention. The participants were completed again one month and three months after the intervention. To understand the users' satisfaction with this APP, only the participants in the experimental group were requested to complete the Inventory of Technology Acceptance Model when completing the questionnaires during the third posttest. The goal was to strengthen parents' symptom management ability and improve their psychosocial functions and children's disease severity.
Patients receiving immunosuppressants, including NULOJIX, are at increased risk of developing bacterial, viral (cytomegalovirus [CMV] and herpes), fungal, and protozoal infections, including opportunistic infections. These infections may lead to serious, including fatal, outcomes [see Boxed Warning and Adverse Reactions (6.1)].

Prophylaxis for cytomegalovirus is recommended for at least 3 months after transplantation. Prophylaxis for Pneumocystis jiroveci is recommended after transplantation.

### Tuberculosis

Tuberculosis was more frequently observed in patients receiving NULOJIX than cyclosporine in clinical trials [see Adverse Reactions (6.1)]. Patients should be evaluated for tuberculosis and tested for latent infection prior to initiating NULOJIX. Treatment of latent tuberculosis infection should be initiated prior to NULOJIX use.

### Polyoma Virus Nephropathy

In addition to cases of JC virus-associated PML [see Warnings and Precautions (5.4)], cases of polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, have been reported. PVAN is associated with serious outcomes; including deteriorating renal function and kidney graft loss [see Adverse Reactions (6.1)]. Patient monitoring may help detect patients at risk for PVAN. Reductions in immunosuppression should be considered for patients who develop evidence of PVAN. Physicians should also consider the risk that reduced immunosuppression represents to the functioning allograft.
Flexibility is a pivotal constituent of the physical fitness and held as an integral aspect that capacitate the person to move smoothly and safely. Although the flexibility of all the muscles of the body is essential for normal human function, the flexibility of hamstring muscle is much emphasized. Investigations suggest adequate flexibility of the Hamstring muscles is compulsory for a healthy lower back. Lack of hamstring muscles extensibility conditions a decrease of pelvic mobility. This invariably leads to biomechanical changes in the pressure distribution of the spine and consequent spinal disorders.

This study will be a randomized control trial and will be conducted in health sciences collage in Bahawalpur. The study will be completed within the time duration of six months. Convenient sampling technique will be used to collect the data. The sample size of 48 patients will be taken in this study to find the Effects of Mulligan's bent leg raise technique on hamstring flexibility and lumber spine mobility in healthy females. Patient will be divided into two groups. Static Stretching will be given to both group as a baseline treatment. (Group A will be treated with Mulligan's bent leg raise techniques and static stretching Group B will be treated with static stretching only. Participants will be assessed for hamstring tightness with Active Knee Extension Test (AKET) and readings will be noted and lumbar mobility will be assess using Modified Schober Test (MMST). Assessments will be done at baseline and post intervention on 5th and 10th day. Intervention will be given 5 days per week for two weeks. Data will be analyzed on SPSS 25.
Participants were prescribed a lead-in with PEG-IFN and RBV for 4 weeks. After the lead-in, BOC was added. Cirrhotic participants received 44 weeks of triple therapy (BOC+PEG-IFN+RBV), and non-cirrhotics received 32 weeks of triple therapy followed by 12 additional weeks of PEG-IFN+RBV.
The capacity to deliver programmes that prevent and control infectious diseases is a key public health function. The European Centre for Disease Prevention and Control (ECDC) aims to support and strengthen this capacity in European Union/ European Economic Area (EU/EEA) countries as part of its 2021-27 strategy which includes explicit attention to social and behavioural aspects of disease prevention. To achieve its strategic goals, it is important that ECDC improves its knowledge of prevention strategies, actors and activities in EU/EEA countries. In this Perspective, we summarise three challenges to implementing the prevention framework proposed by ECDC: (i) defining, recognising and identifying with 'prevention', (ii) integrating new understandings into established ways of thinking, and (iii) the need for more attention to prevention in governance. These challenges are derived from the findings of a project which conducted a preliminary mapping of prevention actors, networks and activities in four EU countries to support the development of a community of practice within the new ECDC prevention framework. This Perspective serves to draw attention to this prevention framework and the three identified challenges for those working on its implementation.
Autophagy participates in the regulation of ferroptosis. Among numerous autophagy-related genes (ATGs), ATG5 plays a pivotal role in ferroptosis. However, how ATG5-mediated ferroptosis functions in UVB-induced skin inflammation is still unclear. In this study, we unveil that the core ferroptosis inhibitor GPX4 is significantly decreased in human skin tissue exposed to sunlight. We report that ATG5 deletion in mouse keratinocytes strongly protects against UVB-induced keratinocyte ferroptosis and skin inflammation. Mechanistically, ATG5 promotes the autophagy-dependent degradation of GPX4 in UVB-exposed keratinocytes, which leads to UVB-induced keratinocyte ferroptosis. Furthermore, we find that IFN-γ secreted by ferroptotic keratinocytes facilitates the M1 polarization of macrophages, which results in the exacerbation of UVB-induced skin inflammation. Together, our data indicate that ATG5 exacerbates UVB-induced keratinocyte ferroptosis in the epidermis, which subsequently gives rise to the secretion of IFN-γ and M1 polarization. Our study provides novel evidence that targeting ATG5 may serve as a potential therapeutic strategy for the amelioration of UVB-caused skin damage.
A malleable demineralized bone composition consists of cortical bone made from a first portion and a second portion. The first portion of cortical bone is made from cut pieces freeze dried then ground into particles and demineralized then freeze-dried. The second portion of cortical bone is shaved into shavings. The shavings are long thin strips subjected to freeze-drying. The freeze-dried shavings are ground and demineralized and then freeze-dried. A volume of the second portion is placed in a solution of sterile water to create a mixture, the water volume being twice the second portion, the mixture is autoclaved under heat and pressure to form a gelatin, and the first portion is mixed with the gelatin to form a malleable putty or paste.
The invention provides a preparation method of a natural product Hirtellanine B. The natural product Hirtellanine B is prepared by taking 2,4,6-trihydroxyaetcophenonem as a raw material through the steps of preparing a compound a, a compound b, a compound c, a compound d, a compound e, a compound f, a compound g and the like. Bioactivity screening is performed on the Hirtellanine B and 14 Hirtellanine B derivatives, and results show that the natural product Hirtellanine B can inhibit proliferation of Jurkat cells, Raji cells and K562 cells, and the natural product Hirtellanine B and the Hirtellanine B derivatives all have the certain inhibitory activity on the tumor cells. The preparation method has the advantages that the raw material is easy to obtain, the reaction yield is high, operation is reasonable, and the method is suitable for industrialized production. The Hirtellanine B and the derivatives thereof can be used for preparing a drug for treating a tumor and have the great clinical application value. The reaction formulas of the preparation method of the natural product Hirtellanine B are shown as the following formulas (please see the formulas in the description).
The Control Group receives no SDM Training. All participants of the Control Group will be offered to participate in the SDM Online Training after T2.
Buddhist meditation practices, including Samadhi meditation, which forms the basis for mindfulness practice, are broadly promoted as pathways to wellbeing, but evidence of their adverse effects is emerging. In a single-group observational study with assessments of autonomic system before, during, and after Samadhi meditation, we explore the relationship between post-meditation nausea symptoms and the degree of change in autonomic system activity during meditation as compared to before and after in 57 university students (42 women; mean age = 22.6) without any previous experience in meditation or yoga practices. We hypothesize that nauseous feelings in meditation are connected to a rapid increase of activity in the sympathetic nervous system, as indicated by decreased heart-rate variability (HRV). We additionally explore links between meditation-induced nausea and two markers of parasympathetic activity: increased HRV and vasovagal syncope. Engaging in meditation and increased nausea during meditation were both associated with increased markers of HRV parasympathetic activity, but 12 individuals with markedly higher nausea demonstrated increased HRV markers of sympathetic activity during meditation. Vasovagal syncope was observed but found to be unrelated to nausea levels. Drivers of adverse effects of meditation in some individuals require further investigation.
STUDY OBJECTIVE: To evaluate the relationship between polycystic ovary syndrome (PCOS), night eating syndrome (NES), and sleep problems in the adolescent population.
METHODS: PCOS patients (n = 43) and healthy controls (n = 62) aged between 15 and 19 years were recruited from the clinics of Adolescent Medicine and Adolescent Gynecology. The Night Eating Questionnaire (NEQ), Pittsburg Sleep Quality Index (PSQI), and Pediatric Sleep Questionnaire-Short Form (PSQ-SF) were completed by the participants.
RESULTS: The PSQI (P = .175), PSQ-SF (P = .320), and NEQ (P = .493) scores were not statistically different between the PCOS and control groups. The NEQ scores were positively correlated with illness duration (r = 0.348, P = .024) in the PCOS group. There was no significant correlation between the NEQ scores and body mass index Z-score, total testosterone and dehydroepiandrosterone sulfate levels, or modified Ferriman-Gallwey Score. The NEQ scores were positively correlated with both the PSQI (r = 0.532, P < .001) and PSQ-SF scores (r = 0.204, P = .037) in the PCOS group. The ratio of adolescents at risk for NES (having an NEQ score ≥25) did not differ significantly between the PCOS and control groups (P = .601).
CONCLUSION: Adolescents with PCOS have NES scores similar to those of healthy controls. This result may change as the duration of exposure to the disease increases. When screening adolescents with PCOS for eating, psychiatric, and sleep problems, they should also be screened for NES due to the high comorbidity rates and symptom overlap of these health conditions.
Carers of food allergic children report that their information needs are greatest at the beginning of their journey when their child first experiences a food allergic reaction. Unfortunately, wait times to attend specialist paediatric allergy clinics can be lengthy. Thus, families can experience a prolonged time-gap between the initial allergic reaction and accessing diagnostic testing and benefitting from multi-disciplinary support and education. Furthermore, carers report often contradictory advice from non-specialist Healthcare Professionals (HCPs). This in turn encourages carers to look for information online with many using search engines unless guided to official food allergy websites by HCPs. Not all online information is correct, or evidence based. Often information provided suggests that certain FA children are at greater risk of anaphylaxis and mortality. This in turn increases anxiety amongst carers and impairs their quality of life.

The purpose of this study is to develop an effective intervention that improves maternal FA related quality of life, anxiety, and self-efficacy prior to attending their child's first paediatric allergy clinic appointment. A randomized control trial will be performed comparing quality of life, anxiety and self efficacy in carers who receive the intervention versus those that do not. Participants will be randomized into 2 groups. All volunteers, from both groups, will complete questionnaires online using only a study identifier number. This will ensure anonymity throughout the study. The only personal information that will be asked is the carer's age group, whether they are a mother or father, their child's age and gender and whether they have any other allergies. Group 1 will be sent a written patient information leaflet displaying ten food allergy myths with the myth-busting evidence-based information clearly stated. Two weeks following the online educational session, Groups 1 and 2 will again complete the online questionnaires.

The outcomes are health related quality of life and levels of anxiety. It is hoped that the findings will positively support Carers, children and their families
Adjuvant treatments has significantly improved the prognosis of early breast cancer patients. However, previous studies suggested the existence of noncompliance to adjuvant therapies, which might cause detriments to disease outcomes. The goal of this multicentric randomized controlled clinical trial is to test the role of mobile medical application (APP) on adjuvant therapy compliance and quality of life (QoL) in patients with early breast cancer. Patients diagnosed with invasive breast cancers after surgery will be randomly assigned to the Ruijin Breast Cancer APP (RJBC-APP) group or the Control group. Those in the RJBC-APP group can receive treatment reminders, matters needing attention as well as science knowledge and they can communicate with the medical staff during adjuvant treatments while follow-up can only be conducted in outpatient clinic for those in the Control group. The primary endpoint is the rate of adjuvant therapy compliance at 12 months after randomization. Secondary endpoints consist of compliance rates at 3, 6, 24 months after randomization, QoL and cancer-related symptoms scores at 3, 6, 12, 24 months, disease-free survival (DFS) and overall survival (OS) at 60 months.
The invention relates to a medical anti-adhesion agent which comprises carboxymethyl chitosan and equilibrium liquid. The solvent of the equilibrium liquid is water for injection, and the solute of the equilibrium liquid comprises sodium chloride and monopotassium phosphate. The anti-adhesion agent comprises, in weight percent, 0.1%-10% of carboxymethyl chitosan, preferably 0.2%-5% of carboxymethyl chitosan, more preferably 0.5%-4.0% of carboxymethyl chitosan, 0.5%-1% of sodium chloride and 0.1%-2% of monopotassium phosphate. The invention further relates to a method for preparing the anti-adhesion agent. The anti-adhesion agent can be in the form of gel or flushing fluid, is used for preventing postoperative adhesion in general surgery department and gynecology and obstetrics, and can also be used for surgical or trauma flushing. The anti-adhesion agent is non-toxic, non-irritant, biodegradable and free of sensitization, and has fine antibacterial activity and anti-adhesion effects.
PURPOSE OF REVIEW: This review reflects on the impact of the COVID-19 pandemic on the field of rheumatology, emphasizing resulting insights related to the risks of viral infections in immunosuppressed patients, vaccine immunogenicity in immunocompromised patients, and immune dysregulation in the setting of viral infection.
RECENT FINDINGS: During the pandemic, global patient registries provided real-time insights into the risk factors associated with severe COVID-19 outcomes in rheumatology patients. Updated evidence-based recommendations from the American College of Rheumatology (ACR) guided rheumatology practice during a time of considerable uncertainty. Studies on COVID-19 vaccines in immunocompromised populations enhanced our understanding of specific immunosuppressive therapies on vaccine efficacy. The immune dysregulation seen in severe COVID-19 underscored a role for immunomodulation in this and other severe infections. Furthermore, novel post-infectious conditions, namely multisystem inflammatory syndrome in children (MIS-C) and Long COVID, reshaped our understanding of post-viral syndromes and revealed novel pathological mechanisms. Lessons from the COVID-19 pandemic demonstrate the power of collaborative research. The scientific revelations from this dreadful time will, nonetheless, benefit the practice of rheumatology for years to come.
BACKGROUND: Although cholecystectomy is a common surgery, it carries higher risks of postoperative complications and mortality for older adults. Age alone is not a reliable predictor of postoperative outcomes, whereas frailty may provide a more accurate assessment of a patient's health and functional status. Frailty, characterized by physical deterioration and reduced resilience, has been shown to predict mortality, prolonged recovery, and morbidity after various surgeries, including cholecystectomy. Thus, incorporating frailty evaluations into preoperative assessments can improve patient outcomes by individualizing treatment strategies. This systematic review and meta-analysis aims to evaluate how well frailty predicts postoperative outcomes following cholecystectomy.
METHODS: In accordance with PRISMA guidelines, we searched PubMed, Embase, and Web of Science on August 14th, 2024, without restrictions on publication year or language. The quality of the studies was assessed using the Newcastle-Ottawa scale, and meta-analysis was conducted using odds ratios with 95% confidence intervals as the effect size, employing a random-effects model.
RESULTS: Nine cohort studies comprising a total of 128,421 participants were included. The pooled results showed significantly higher odds of short-term mortality (OR: 5.54, 95% CI: 1.65-18.60, p = 0.006), postoperative morbidity (OR: 2.65, 95% CI: 1.51-4.64, p = 0.001), major morbidity (OR: 3.61, 95% CI: 1.52-8.59), and respiratory failure (OR: 3.85, 95% CI: 1.08-13.79) among frail patients. Additionally, frail patients had longer hospital stays (mean difference: 2.98 days, 95% CI: 1.91-4.04) and significantly higher odds of postoperative infection and sepsis. However, no association was evident with reoperation rates.
CONCLUSION: This study highlights the value of utilizing frailty assessment tools in preoperative settings for predicting outcomes after cholecystectomy. These tools could improve decision-making in both emergency and elective situations, aiding in the choice between surgical and medical management, as well as between open and laparoscopic procedures tailored to each patient.
Enteral Nutrition (EN) will be initiated within the first 24-48 hours of ICU. Admission. Enteral nutrient delivery is gradually increased to avoid the possibility of gastrointestinal intolerance so that a few days are required to achieve the caloric target. PN will be started after 5-7 days if EN is not feasible. Energy and protein goals will be calculated by the standard weight-based equation of 25 kcal/kg BW body weight and 1.2-2.5 g/kg body weight, respectively.
<P>PROBLEM TO BE SOLVED: To provide a method for safely generating hydrogen sulfide gas in the stomach including using a substance used as health food product and having no problem in safety; and to provide health food product and drug medicine each enabling generation of hydrogen sulfide gas in the stomach.  <P>SOLUTION: The method for safely generating hydrogen sulfide gas in the stomach includes making a substance made of an acid stronger than the hydrosulfuric acid and hydrogen gas-occluded hermatype calcium react with stomach acid to generate hydrogen sulfide gas in the stomach. The substance made of the acid stronger than the hydrosulfuric acid comprises a lactic acid oligomer. The substance made of the acid stronger than the hydrosulfuric acid, and the hydrogen gas-occluded hermatype coral calcium, are orally taken at the same time. The substance made of the acid stronger than the hydrosulfuric acid suitably comprises the lactic acid oligomer.  <P>COPYRIGHT: (C)2011,JPO&INPIT
The present invention relates to a pharmaceutical composition, a functional health food, and a feed composition, for innate immune-boosting and antiviral purposes, containing an Albizziae Cortex extract as an active ingredient. The present invention further relates to a method for boosting innate immunity and increasing antiviral activities in animals, including a step of injecting the Albizziae Cortex extract into animals requiring enhancement of innate immunity, not including human. According to the present invention, the Albizziae Cortex composition for innate immune-boosting and antiviral purposes shows effectiveness in boosting innate immunity and antiviral activities, and thus the composition can be used for preventing and treating infectious disease caused by bacteria and virus. In addition, the Albizziae Cortex composition can be widely used as drugs or functional health foods for boosting and regulating immunity in a patient with weakened or suppressed immunity, and also as feeds for innate immune-boosting and antiviral purposes for strengthening an anti-disease immune system in animals. Furthermore, the composition for innate immune-boosting and antiviral purposes, according to the present invention, barely causes toxicity or side effects. Thus, the composition can be used with ease even for a long period of time in order to prevent disease.
We anticipate enrolling 12 clinicians (including physicians, nurse practitioners, physician assistants, mental health providers, other advanced practice clinicians) who treat patients with colorectal cancer at the University of Colorado to participate in qualitative interviews. We seek to enroll a variety of clinicians from advanced practiced clinical roles (physicians, nurse practitioners, and mental health providers) to capture diverse perspectives.